Marc de Garidel, CinCor Pharma CEO (Eric Piermont/AFP via Getty Images)

Weeks af­ter $143M megaround, low-pro­file Cin­Cor looks to vault on­to Nas­daq with a Roche castoff

Cin­Cor Phar­ma made some noise ear­li­er this year af­ter rais­ing $143 mil­lion in a Se­ries B in Oc­to­ber, thanks to a round led by Gen­er­al At­lantic. And now CEO Marc de Garidel, the for­mer chair­man and CEO of Ipsen who came on board the biotech in Ju­ly, is mov­ing for­ward — gun­ning for a spot on Nas­daq.

The Cincin­nati-based, Sofinno­va-backed biotech — found­ed in 2018 and spun out from par­ent com­pa­ny Cin­Rx Phar­ma — filed an S-1 on Fri­day, pen­cil­ing in $100 mil­lion for the raise. As for what the biotech plans to do with what­ev­er amount it ul­ti­mate­ly wants to raise, it’s all go­ing in­to Cin­Cor’s on­ly drug can­di­date: CIN-107, an oral al­dos­terone syn­thase in­hibitor that co-founders Jon Isaac­sohn and Cather­ine Pearce li­censed from Roche for ini­tial­ly $3 mil­lion back in 2019, ac­cord­ing to the S-1. Al­dos­terone is a hor­mone linked to in­creased blood pres­sure, and has been a tar­get of in­ter­est to treat hy­per­ten­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.